Body Contouring For GLP-1 Patients: Evaluating Ultherapy PRIME
According to a study in May 2024, approximately 12% of American adults have taken GLP-1 medications, with 6% of people polled actively taking them at the time of the survey. The number of patients now experiencing successful weight loss has created a distinct patient subset with a new primary concern: GLP-1 skin laxity.
While the term “Ozempic face” has gained widespread attention for facial volume loss, a significant number of patients now present with loose skin on the body.
McKinsey research indicates 61% of GLP-1 patients seeking aesthetic treatment have lost 11-30% of their body weight, and rapid weight loss often does not allow sufficient time for the skin to remodel.
This has created a surge in demand for body contouring after weight loss. For practitioners, the question is no longer just about managing weight, but about offering effective non-surgical tightening solutions. This article explores Ultherapy PRIME as a primary option for this growing demographic.
In this article, you'll learn:
- How to identify ideal candidates for non-surgical body contouring among your GLP-1 patient population
- The clinical evidence and FDA clearance timeline supporting Ultherapy PRIME for body treatments
- Safe combination therapy approaches to maximize results and revenue per patient
- The business case for integrating body contouring into medical weight management or aesthetic practices
Table of Contents
A Brief History of Ultherapy FDA Clearances
To understand the significance of the new body indications, it is helpful to review the device’s regulatory journey.
- 2009: Initial FDA clearance for non-invasive eyebrow lift.
- 2012: Expanded clearance for lifting lax submental (under the chin) and neck tissue.
- 2014: Additional clearance to improve the appearance of lines and wrinkles on the décolleté.
- 2024: Introduction of the Ultherapy PRIME system, featuring a 20% faster treatment time.
- 2025: The most recent clearance for improving the appearance of skin laxity on the anterior arms, posterior arms, and abdomen.
Patient Selection: Who Benefits Most from Body Contouring for GLP-1 Patients?
- Mild to moderate GLP-1 skin laxity (not severe redundant skin requiring surgical excision)
- Post-weight loss concerns where fat volume is no longer the primary issue
- Specific anatomical concerns such as crepey, loose skin on the arms or abdomen
- A motivation for non-surgical tightening options due to lifestyle, recovery time, or risk tolerance
- Realistic expectations about the degree of improvement achievable with non-invasive technology
Clinical Scenarios & Suitability
- High Suitability: A GLP-1 user who has lost 25-30% of their body weight and now has mild arm laxity. Their primary concern is the inability to wear sleeveless clothing comfortably. This is a prime candidate for skin tightening on the arms after weight loss, and Ultherapy PRIME directly addresses this without surgery .
- Low Suitability: A post-bariatric surgery patient with massive weight loss and a severe abdominal apron. The significant skin redundancy in this case likely requires surgical intervention, as non-surgical abdomen tightening after weight loss would be insufficient.
- Moderate to High Suitability: A postpartum patient with mild abdominal laxity and no diastasis recti. The suitability depends on the degree of laxity, but it can be an effective non-surgical option for addressing loose skin.
- Moderate Suitability: A medical weight loss patient who has lost 15% of their body weight and is concerned about future laxity. They may benefit from earlier intervention as a preventive non-surgical skin tightening measure.
Combination Therapy Considerations
While Ultherapy PRIME is effective as a standalone treatment, clinical experience suggests that a multi-modality approach can lead to enhanced results for certain patients. The key is to combine treatments that work on different tissue depths and via complementary mechanisms of action.
Here are some common treatments it can safely be combined with:
- Injectable Biostimulators: Hyperdilute Radiesse (calcium hydroxyapatite) can be used to improve dermal thickness and skin quality.
- Liposuction: For patients with residual small pockets of fat, liposuction can be performed in conjunction with skin tightening.
- Other Energy-Based Devices: Devices using different energy sources (e.g., radiofrequency) can be used to address different aspects of skin aging.
Practice Integration: The Business Case for Medical Weight Loss Aesthetics
For Medical Weight Management Practices:
- Opportunity: 63% of GLP-1 patients seeking aesthetic treatments are new to the aesthetic market
- Patient Retention: Addressing GLP-1 skin laxity concerns keeps patients within your practice.
- Consideration: Requires capital investment in equipment and staff training for body contouring after weight loss.
For Established Aesthetic Practices:
- Opportunity: Expand to body treatments with a single platform, as Ultherapy PRIME covers both face and body.
- Market Timing: The skin-lifting market is projected to grow approximately 9% by 2030 5 .
- Consideration: Requires training on new anatomical safety zones for body contouring for GLP-1 patients .
Anatomical and Safety Considerations
Critical No-Treatment Zones:
- Direct treatment over the umbilicus is contraindicated.
- The ulnar nerve pathway on the posterior arm must be avoided.
- Real-time visualization is a key feature for identifying appropriate treatment depth and avoiding these zones.
Training Requirements:
- A strong understanding of body anatomy beyond facial structures.
- Proficiency with real-time ultrasound visualization.
Note: Body contouring and skin tightening training, including technologies like Ultherapy, is included in IAPAM’s Certified Aesthetic Provider™ (CAP) program for practitioners seeking comprehensive education in this area.
Limitations and Alternatives
When Ultherapy PRIME May Not Be Appropriate:
- Severe loose skin requiring surgical excision.
- Patients with unrealistic expectations.
- Active skin infections or inflammatory conditions in the treatment area.
Alternative or Complementary Technologies:
- Radiofrequency devices
- Laser skin tightening
- Surgical body contouring after weight loss (abdominoplasty, brachioplasty)
- Injectable biostimulators as standalone or adjunct therapy
Conclusion: Strategic Considerations for Your Practice
The FDA clearance of Ultherapy PRIME for body treatments addresses a clinical need amplified by the GLP-1 patient population. For practices serving this demographic, offering body contouring for GLP-1 patients represents a logical extension of care.
The decision to integrate this service should be based on a careful analysis of your patient base, practice model, and capacity for investment and training.
For those who can offer comprehensive solutions—from weight management through aesthetic restoration—this trend presents a significant opportunity in medical weight loss aesthetics.
Aesthetic Medicine Certification & Excellence
Earn your certification and designation as trusted Certified Aesthetic Provider™ (CAP) and show your patients your commitment to the highest standards in training and care.
From Botox® and fillers to PRP, PDO threads, chemical peels and more, this is your one stop shop for CME-accredited training from an internationally-recognized association with 20 years of aesthetic medicine excellence.
Sources:
- American Med Spa Association. (2025, November 5). New Indications: Merz Aesthetics’ Ultherapy PRIME Gains FDA Clearance for Abdomen, Anterior and Posterior Arms.
- NewBeauty. (2025, November 5 ). FDA Clears Ultherapy PRIME for Arm and Abdomen Tightening.
- The Dermatology Digest. (2025, November 5 ). U.S. FDA Clears Ultherapy PRIME to Treat Skin Laxity on the Arms and Abs.
- Salisbury Plastic Surgery / McKinsey Research. (2025, November 7 ). Fat Transfer for Ozempic Face: Complete Guide to Facial Volume Restoration After GLP-1 Weight Loss.
- Merz Custom Market Forecasting. (2025 ). Skin Lifting Market Growth Projections 2025-2030. (As cited in NewBeauty)
- KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs
- Ultherapy Prime For Healthcare Providers.
